Spinal cord injury treated successfully using new drug

(1888 PressRelease) First successful spinal cord treatment using a non-invasive stem-cell topical drug.

New York, NY - The world's first success in treating spinal cord injury sustained more than 40 years ago has been demonstrated using a new non-invasive drug.

The treatment relies on a new formulation that creates stem cells deep below the skin using a highly-penetrating ointment. The drug is delivered using technology similar to that used in nicotine patches. TetraStem is a new tetracycline-based topical antibiotic that is FDA registered to treat cuts and burns. It was discovered 5 years ago that, as a new off-label drug, it also can induce stem-cell healing; first in an animal research program followed by human research programs.

Older spinal cord injuries have been notoriously impossible to treat. Paraplegics and quadraplegics have tended to remain paraplegics and quadraplegics. Now, what was impossible may become possible using this new stem-cell drug. Good results have been obtained after treatment of a spinal cord injury sustained 42 years ago. The research methodology and case study results are online at http://www.PhillipsCompany.4T.com/SCAR.pdf

The new treatment is the world's first low-cost treatment for spinal cord injury. Hospitalization is not required because the non-invasive stem-cell drug can be applied topically, and there are no known side effects. For a limited time, the manufacturer is offering the new drug to any paraplegic.

Miranda is the first patient to benefit from this simple but effective experimental drug. As a complete paraplegic, she became the first person on earth to walk again as result of using the simple rub-it-on-the-skin drug for six months. Miranda's treatment and progress is reported online at http://www.PhillipsCompany.4T.com/Miranda.pdf

Because Miranda's treatment began only a few days following her spinal cord injury, it was first thought that perhaps the successful outcome using the new drug might be helpful only as an early-intervention treatment -- but a better expectation has been established based on recent data.

Phillips Company invites any hospital or orthopedic surgeon to evaluate this new drug for the treatment of patients with spinal cord injury.

The new ointment is being developed by the world's only not-for-profit FDA-registered drug manufacturing company. Phillips Company is a develop-and-license company. TetraStem will be transferred to a larger pharmaceutical company for high-volume production.


Contact Details

Company Name: 1888PressRelease
Issued By: Donald Hood
Phone: 0000000000
Address: New York
City: New York
State: New York
Zip: 10001
Country: United States
Website: Visit the website

Keywords : Healthcare, Drug, Industry, News,

by Donald Hood (few months ago!)

Latest Press Releases

Text My Main Number Announced Major Shift of US Businesses toward Landline Texting

Global Department Stores Retailing 2015-2020: Ken Research

Global M-Health Device Market : Latest Research

Global Zinc Selenide Market Professional Survey Report 2017 to its Products Forecast – RAIN G..

Diesel Fuel Injection Systems 2017 Development, Trends, Share, Growth, Research and Market An..

Global Soil Testing, Inspection, and Certification Market Size, Status – ALS Ltd, Assure Qual..

Silicon Carbide Ceramics 2017 Annual Growth Value, Market Trends, Developments & Opportunities

5.1% CAGR Anticipated for Demineralized Whey Powder Ingredient Market During 2017-2027

Acoustic Wall Panels Market Forecasts, Size, Share, Regional Outlook 2017 to 2022

Rehm goes India

Remove this press release ?

Due to extra work required to remove the press-releases we have started charging $1.99 for press release removal.

Your press release will be removed in 24 hours, once the payment has been received.

Search Press Release
e.g. Business, Computer, etc.